<VariationArchive VariationID="1459947" VariationName="NC_000004.11:g.(?_159611480)_(159620302_?)del" VariationType="Deletion" Accession="VCV001459947" Version="5" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-17" DateCreated="2022-03-28" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1481304" VariationID="1459947">
      <GeneList>
        <Gene Symbol="ETFDH" FullName="electron transfer flavoprotein dehydrogenase" GeneID="2110" HGNC_ID="HGNC:3483" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>4q32.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="158672296" stop="158709623" display_start="158672296" display_stop="158709623" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="159593276" stop="159629841" display_start="159593276" display_stop="159629841" Strand="+" />
          </Location>
          <OMIM>231675</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000004.11:g.(?_159611480)_(159620302_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>4q32.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" innerStart="159611480" innerStop="159620302" display_start="159611480" display_stop="159620302" variantLength="8823" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.11" sequenceAccession="NC_000004" sequenceVersion="11" change="g.(?_159611480)_(159620302_?)del" Assembly="GRCh37">
            <Expression>NC_000004.11:g.(?_159611480)_(159620302_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000004.11:g.(?_159611480)_(159620302_?)del AND Multiple acyl-CoA dehydrogenase deficiency" Accession="RCV001963200" Version="5">
        <ClassifiedConditionList TraitSetID="3248">
          <ClassifiedCondition DB="MedGen" ID="C0268596">Multiple acyl-CoA dehydrogenase deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-06-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-06-20" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-03-28" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">19758981</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3248" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5563" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">GA II</ElementValue>
                <XRef Type="MIM" ID="231680" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ethylmalonic-adipicaciduria</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glutaric aciduria, type 2</ElementValue>
                <XRef ID="Glutaric+Acidemia+II/3111" DB="Genetic Alliance" />
                <XRef ID="22886006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Multiple acyl-CoA dehydrogenase deficiency</ElementValue>
                <XRef ID="MONDO:0009282" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glutaric acidemia type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glutaric acidemia type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GA 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">EMA</ElementValue>
                <XRef Type="MIM" ID="231680" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">MADD</ElementValue>
                <XRef Type="MIM" ID="231680" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6523" />
                <XRef ID="6523" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Multiple acyl-CoA dehydrogenase deficiency (MADD) represents a clinical spectrum in which presentations can be divided into type I (neonatal onset with congenital anomalies), type II (neonatal onset without congenital anomalies), and type III (late onset). Individuals with type I or II MADD typically become symptomatic in the neonatal period with severe metabolic acidosis, which may be accompanied by profound hypoglycemia and hyperammonemia. Many affected individuals die in the newborn period despite metabolic treatment. In those who survive the neonatal period, recurrent metabolic decompensation resembling Reye syndrome and the development of hypertrophic cardiomyopathy can occur. Congenital anomalies may include dysmorphic facial features, large cystic kidneys, hypospadias and chordee in males, and neuronal migration defects (heterotopias) on brain MRI. Individuals with type III MADD, the most common presentation, can present from infancy to adulthood. The most common symptoms are muscle weakness, exercise intolerance, and/or muscle pain, although metabolic decompensation with episodes of rhabdomyolysis can also be seen. Rarely, individuals with late-onset MADD (type III) may develop severe sensory neuropathy in addition to proximal myopathy.</Attribute>
                <XRef ID="NBK558236" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">32550677</ID>
                <ID Source="BookShelf">NBK558236</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Glutaric-Aciduria-Type-2-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C4 and C5 +/- Other Acylcarnitines, Glutaric Acidemia II (GA-II) (MADD), 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm,">
                <URL>https://www.acmg.net/PDFLibrary/C4-C5-Elevated-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Glutaric Acidemia II (GA-II)/ MADD, Riboflavin Metabolism Disorder, Ethylmalonic Encephalopathy: C4 and C5 elevated +/- other elevated acylcarnitines (AC), 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2021">
                <URL>https://www.acmg.net/PDFLibrary/C8-C6-C10.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C8 with Lesser Elevations of C6 and C10 Acylcarnitine, Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency, 2021</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2021">
                <URL>https://www.acmg.net/PDFLibrary/C8-C6-C10-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, C8 Elevated + Lesser Elevations of C6 and C10, 2021</CitationText>
              </Citation>
              <XRef ID="26791" DB="Orphanet" />
              <XRef ID="C0268596" DB="MedGen" />
              <XRef ID="MONDO:0009282" DB="MONDO" />
              <XRef Type="MIM" ID="231680" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4262609" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="NM_004453.3_4_Deletion (exons 6-9)|MedGen:C0268596" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002243876" DateUpdated="2024-06-09" DateCreated="2022-03-28" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-06-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">19758981</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exon(s) 6-9 of the ETFDH gene. This variant would be expected to be in-frame, preserving the integrity of the reading frame. This variant has not been reported in the literature in individuals affected with ETFDH-related conditions. This variant disrupts a region of the ETFDH protein in which other variant(s) (p.Val291Gly) have been determined to be pathogenic (PMID: 19758981). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ETFDH" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000004.11:g.(?_159611480)_(159620302_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268596" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4262609" TraitType="Disease" MappingType="XRef" MappingValue="C0268596" MappingRef="MedGen">
        <MedGen CUI="C0268596" Name="Multiple acyl-CoA dehydrogenase deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

